Here’s what you should know.
1. The company hopes to verify the breathalyzer’s effectiveness in diagnosing colorectal cancer.
2. The breathalyzer uses “field asymmetric ion mobility spectrometry” to detect organic compounds in a person’s breath. The sensor looks for biomarkers that identify colorectal cancer.
3. In a pilot study, the breathalyzer had an 88 percent accuracy rate.
4. Owlstone recently completed an $11.6 million funding round, following an original investment of $7 million. The company plans to use those funds to bring the breathalyzer to commercialization.
More articles on gastroenterology/endoscopy:
GI leader to know: Dr. Indira Reddy of Wake Endoscopy Center
Can pregnant women undergo endoscopy? 3 study insights
Takeda maintains commitment to drug pricing plan as Trump demands lower prices & more — 3 GI companies making waves
